Article

High conformal RT doses improve PSA, increase toxicity

Orlando, FL-Conformal radiotherapy to the prostate with isocenterdoses of 78 Gy lowers biochemical failure by at least 6% at 6 years, andby as much as 19% for men at higher risk of cancer relapse. But the costis a 14% increase in mild to moderate risk of rectal toxicity, accordingto two reports presented at the American Society of Clinical Oncology annualmeeting.

Related Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
Woman having telemedicine appointment with doctor | Image Credit: © Jacob Lund - stock.adobe.com
Alexander Pastuszak, MD, PhD: Is hormone therapy safe after prostate cancer radiotherapy?
Related Content
Health Canada approves expanded indication of Illuccix in prostate cancer
October 7th 2024

Health Canada approves expanded indication of Illuccix in prostate cancer

Hannah Clarke
Illuccix is now indicated for use in the selection of patients with mCRPC for PSMA-targeted radionuclide therapy.
Key updates from the AUA/ASRM male infertility guideline amendment
September 23rd 2024

Key updates from the AUA/ASRM male infertility guideline amendment

Urology Times staff
In this episode, Robert E. Brannigan, MD, and Juan J. Andino, MD, MBA, discuss the recent amendment to the AUA/ASRM guideline on male infertility.
Senior doctor asking elderly patient questions | Image Credit: © rocketclips - stock.adobe.com
October 7th 2024

Wayne G. Brisbane, MD, discusses AI-assisted HIFU for prostate cancer

Urology Times staff
"I think it's a really nice synergy between the 2 technologies," says Wayne G. Brisbane, MD.
Speaking of Urology: Dr. Winter on the use of vaginal estrogen
July 24th 2024

Speaking of Urology: Dr. Winter on the use of vaginal estrogen

Urology Times staff
In this episode of Speaking of Urology®, Ashley G. Winter, MD, discusses the use of vaginal estrogen.
Study to compare TLX250-CDx vs contrast-enhanced CT for recurrent ccRCC
October 4th 2024

Study to compare TLX250-CDx vs contrast-enhanced CT for recurrent ccRCC

Hannah Clarke
“We are pleased that a first patient has been imaged in the CA-NINE trial, which supports potential label expansion for TLX250-CDx into recurrent, metastatic disease,” says David N. Cade.
Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
October 3rd 2024

Ra223 plus SABR does not delay progression of oligometastatic HSPC

Benjamin P. Saylor
"The addition of radium-223 to SABR metastasis-directed therapy in low-volume bone-metastatic hormone-sensitive prostate cancer does not delay progression of disease in the RAVENS study," said Ana Kiess, MD, PhD.
© 2024 MJH Life Sciences

All rights reserved.